Sandbox vidit: Difference between revisions

Jump to navigation Jump to search
Line 55: Line 55:
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Amiodarone]] (100 to 400 mg)'''''<BR>''OR''<BR>▸ '''''[[Disopyramide]] (400 to 750 mg)'''''<BR>''OR''<BR> ▸ '''''[[Dofetilide]] (500 to 1000 mcg)'''''<BR>''OR''<BR>▸ '''''[[Flecainide]] (200 to 300 mg)'''''<BR>''OR''<BR>▸ '''''[[Procainamide]] (1000 to 4000 mcg)'''''<BR>''OR''<BR>▸ '''''[[Propafenone]] (450 to 900 mg)'''''<BR>''OR''<BR>▸ '''''[[Quinidine]] (600 to 1500 mg)'''''<BR>''OR''<BR>▸ '''''[[Sotalol]] (160 to 320 mg)'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Amiodarone]] (100 to 400 mg)'''''<BR>''OR''<BR>▸ '''''[[Disopyramide]] (400 to 750 mg)'''''<BR>''OR''<BR> ▸ '''''[[Dofetilide]] (500 to 1000 mcg)'''''<BR>''OR''<BR>▸ '''''[[Flecainide]] (200 to 300 mg)'''''<BR>''OR''<BR>▸ '''''[[Procainamide]] (1000 to 4000 mcg)'''''<BR>''OR''<BR>▸ '''''[[Propafenone]] (450 to 900 mg)'''''<BR>''OR''<BR>▸ '''''[[Quinidine]] (600 to 1500 mg)'''''<BR>''OR''<BR>▸ '''''[[Sotalol]] (160 to 320 mg)'''''
|-
|}
|}
==Heart Rate Control==
Shown below is a table summarizing the list of recommended agents for control of heart rate and their dosages.<ref name="Fuster-2011">{{Cite journal  | last1 = Fuster | first1 = V. | last2 = Rydén | first2 = LE. | last3 = Cannom | first3 = DS. | last4 = Crijns | first4 = HJ. | last5 = Curtis | first5 = AB. | last6 = Ellenbogen | first6 = KA. | last7 = Halperin | first7 = JL. | last8 = Kay | first8 = GN. | last9 = Le Huezey | first9 = JY. | title = 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. | journal = Circulation | volume = 123 | issue = 10 | pages = e269-367 | month = Mar | year = 2011 | doi = 10.1161/CIR.0b013e318214876d | PMID = 21382897 }}</ref>
{| style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center; colspan="3"| {{fontcolor|#FFF|Heart Rate Control in Acute Setting}}
|-
| style="padding: 0 5px; font-size: 100%; background: #F5F5F5;" align=center | '''Drug'''|| style="padding: 0 5px; font-size: 100%; background: #F5F5F5;" align=center | '''Loading dose''' || style="padding: 0 5px; font-size: 100%; background: #F5F5F5;" align=center | '''Maintenance dose'''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center; colspan="3" | '''''Heart rate control in patients without [[accessory pathway]]'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Esmolol]] <br>([[ACC AHA guidelines classification scheme|class I, level of evidence C]])''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''500 mcg/kg IV over 1 min''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''60 to 200 mcg/kg/min IV'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Propanolol]] <br>([[ACC AHA guidelines classification scheme|class I, level of evidence C]])''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.15 mg/kg IV''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''NA'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Metoprolol]] <br>([[ACC AHA guidelines classification scheme|class I, level of evidence C]])''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''2.5 to 5 mg IV bolus over 2 min; up to 3 doses''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''NA'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Diltiazem]] <br>([[ACC AHA guidelines classification scheme|class I, level of evidence B]])''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.25 mg/kg IV over 2 min''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''5 to 15 mg/h IV'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Verapamil]] <br>([[ACC AHA guidelines classification scheme|class I, level of evidence B]])''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.075 to 0.15 mg/kg IV over 2 min''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''NA'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center; colspan="3" | '''''Heart rate control in patients with [[accessory pathway]]'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Amiodarone]] <br>([[ACC AHA guidelines classification scheme|class IIa, level of evidence C]])''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''150 mg over 10 min''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.5 to 1 mg/min IV'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center; colspan="3" | '''''Heart Rate Control in patients with [[heart failure]] and without [[accessory pathway]]'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Digoxin]] <br>([[ACC AHA guidelines classification scheme|class I, level of evidence B]])''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.25 mg IV each 2 h, up to 1.5 mg''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.125 to 0.375 mg daily IV or orally'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Amiodarone]] <br>([[ACC AHA guidelines classification scheme|class IIa, level of evidence C]])''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''150 mg over 10 min''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.5 to 1 mg/min IV'''''
|-
| style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center colspan="3"| {{fontcolor|#FFF|'''Heart Rate Control in Non Acute Setting and Long Term Maintenance'''}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center; colspan="3" | '''''Heart rate control'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Metoprolol]] <br>([[ACC AHA guidelines classification scheme|class I, level of evidence C]])''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''25 to 100 mg twice a day, orally''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''25 to 100 mg twice a day, orally'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Propanolol]] <br>([[ACC AHA guidelines classification scheme|class I, level of evidence C]])''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''80 to 240 mg daily in divided doses, orally''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''80 to 240 mg daily in divided doses, orally'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Verapamil]] <br>([[ACC AHA guidelines classification scheme|class I, level of evidence B]])''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''120 to 360 mg daily in divided doses, orally''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''120 to 360 mg daily in divided doses, orally'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Diltiazem]] <br>([[ACC AHA guidelines classification scheme|class I, level of evidence B]])''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''120 to 360 mg daily in divided doses, orally''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''120 to 360 mg daily in divided doses, orally'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center; colspan="3" | '''''Heart Rate Control in patients with heart failure and without accessory pathway'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Digoxin]] <br>([[ACC AHA guidelines classification scheme|class I, level of evidence B]])''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.5 mg by mouth daily''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.125 to 0.375 mg daily, orally'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Amiodarone]] <br>([[ACC AHA guidelines classification scheme|class IIb, level of evidence C]])''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''800 mg daily for 1 week, orally <br> 600 mg daily for 1 week, orally <br> 400 mg daily for 4 to 6 week, orally''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''200 mg daily, orally'''''
|-
|-
|}
|}
|}
|}

Revision as of 19:25, 10 March 2014

 
 
 
 
 
 
Atrial flutter
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Unstable
 
 
 
 
 
Stable
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Look for the presence of any of these:
❑ Chronic heart failure
❑ Hypotension
❑ Acute myocardial infarction
 
 
 
 
 
❑ Administer anticoagulation therapy based on the risk of stroke, if total duration of flutter > 48 hours
❑ Administer rate control therapy (AV nodal blockers)

THEN

❑ Attempt conversion
❑ DC cardioversion
❑ Atrial pacing
❑ Pharmacological cardioversion
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Assess need for therapy to prevent recurrence
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Administer antiarrythmic therapy to prevent recurrences
❑ Consider catheter ablation if antiarrhythmic therapy fails
 
 
 
 
 
 
 
 
 
 

Anticoagulation Therapy

Shown below are tables depicting the assessment of risk of stroke and the appropriate anticoagulation therapy among patients with Atrial flutter.[1]

Anticoagulation Therapy
No risk factors Aspirin 81-325 mg daily
1 Moderate risk factor Aspirin 81-325 mg daily
OR
Warfarin (INR 2.0 to 3.0, target 2.5)
Any high risk factor or
more than 1 moderate risk factor
Warfarin (INR 2.0 to 3.0, target 2.5)


Low Risk Factors Moderate Risk Factors High Risk Factors
Female gender
Age 65-74 years
Coronary artery disease
Thyrotoxicosis
Age ≥ 75 years
Hypertension
Heart failure
LV ejection fraction ≤ 35%
Diabetes mellitus
Previous stroke, TIA or embolism
Mitral stenosis
Prosthetic heart valve

Antiarrhythmic Therapy

Maintenance of Sinus Rhythm
Amiodarone (100 to 400 mg)
OR
Disopyramide (400 to 750 mg)
OR
Dofetilide (500 to 1000 mcg)
OR
Flecainide (200 to 300 mg)
OR
Procainamide (1000 to 4000 mcg)
OR
Propafenone (450 to 900 mg)
OR
Quinidine (600 to 1500 mg)
OR
Sotalol (160 to 320 mg)
  1. Fuster, V.; Rydén, LE.; Cannom, DS.; Crijns, HJ.; Curtis, AB.; Ellenbogen, KA.; Halperin, JL.; Kay, GN.; Le Huezey, JY. (2011). "2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines". Circulation. 123 (10): e269–367. doi:10.1161/CIR.0b013e318214876d. PMID 21382897. Unknown parameter |month= ignored (help)